A Phase 3 interventional study of Tofersen and Placebo in Amyotrophic Lateral Sclerosis, sponsored by Biogen. Completed at 40 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-28.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Amyotrophic Lateral Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · Biogen.
Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, this one is one of 2 that started in 2016, is one of 2 in phase 3, and was the 2nd registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →2 of the 11 studies in Amyotrophic Lateral Sclerosis by Biogen are open now, in 1 country. Recruiting first, the newest first:
Biogen · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2016.
This study's enrollment of 176 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 99 across the 9 interventional studies, 132 across the 2 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
2 of the studies in Amyotrophic Lateral Sclerosis by Biogen that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07223723BiogenA Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | 2027-05-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of Parts A and B of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of tofersen in adults with ALS and a documented superoxide dismutase 1 (SOD1) mutation. The primary objective of Part C of this study is to evaluate the clinical efficacy of tofersen administered to adults with ALS and a confirmed SOD1 mutation.
The secondary objective of Parts A and B of this study is to evaluate the effects of tofersen on levels of total SOD1 protein in the cerebrospinal fluid (CSF). The secondary objectives of Part C are to evaluate the safety, tolerability, pharmacodynamic (PD), and biomarker effects of tofersen.
This is a 3-part study to examine the efficacy, safety, tolerability, PK, and PD of tofersen. Part A is the single ascending dose (SAD) component of the study, Part B is the multiple ascending dose (MAD) component of study and Part C is the fixed dose component of the study. Hence, the overall phase of development of the study is 1/2/3.
The study completed on 16 Jul 2021. In total, the study enrolled 176 participants, of which 108 enrolled in Part C.
Key Inclusion Criteria: Part A and B
Key Exclusion Criteria: Part A and B
Key Inclusion Criteria: Part C
Key Exclusion Criteria: Part C
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered tofersen-matching placebo once by intrathecal bolus injection on Day 1 of Cohorts 1, 2, 3, and 4 respectively.
Drug: Placebo
Participants will be administered tofersen 10 mg once by intrathecal bolus injection on Day 1.
Drug: Tofersen
Participants will be administered tofersen 20 mg once by intrathecal bolus injection on Day 1 of Cohort 2 after the safety review of Cohort 1.
Drug: Tofersen
Participants will be administered tofersen 40 mg once by intrathecal bolus injection on Day 1 of Cohort 3 after the safety review of Cohort 2.
Drug: Tofersen
Participants will be administered tofersen 60 mg once by intrathecal bolus injection on Day 1 of Cohort 4 after the safety review of Cohort 3.
Drug: Tofersen
Participants will be administered tofersen-matching placebo, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection.
Drug: Placebo
Participants will be administered tofersen 20 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection.
Drug: Tofersen
Participants will be administered tofersen 40 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety and PK review of Cohort 5.
Drug: Tofersen
Participants will be administered tofersen 60 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety, PK review and SOD1 PD review of Cohort 6.
Drug: Tofersen
Participants will be administered tofersen 100 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety, PK review and SOD1 PD review of Cohort 7.
Drug: Tofersen
Participants will be administered tofersen-matching placebo, 3 loading doses administered once every 2 weeks on Days 1, 15, 29 followed by 5 maintenance doses administered once every 4 weeks on Days 57, 85, 113, 141, 169 up to 24 weeks by intrathecal bolus injection.
Drug: Placebo
Participants will be administered tofersen 100 mg, 3 loading doses administered once every 2 weeks on Days 1, 15, 29 followed by 5 maintenance doses administered once every 4 weeks on Days 57, 85, 113, 141, 169 up to 24 weeks by intrathecal bolus injection.
Drug: Tofersen
Administered as specified in the treatment arm.
Also known as: BIIB067, QALSODY
Administered as specified in the treatment arm.
Parts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.
Time frame: Part A: First dose up to Day 63; Part B: First dose up to Day 289
Parts A and B: Number of Participants With Clinically Significant Laboratory Abnormalities
Clinical laboratory assessments included hematology, chemistry, and urinalysis.
Time frame: Part A: Up to Day 57; Part B: Up to Day 169
Parts A and B: Number of Participants With Clinically Significant Vital Sign Abnormalities
The criteria for clinically significant vital sign abnormalities include: Temperature: \>38 degree Celsius (°C) or an increase from baseline of ≥1°C; Pulse: \>120 beats per minute (bpm) or an increase from baseline of \>20 bpm, \<50 bpm or a decrease from baseline of \>20 bpm; Systolic blood pressure (BP): \>180 mmHg or an increase from baseline of \>40 mmHg, \<90 mmHg or a decrease from baseline of \>30 mmHg; Diastolic BP: \>105 mmHg or an increase from baseline of \>30 mmHg, \<50 mmHg or a decrease from baseline of \>20 mmHg.
Time frame: Part A: Up to Day 57; Part B: Up to Day 169
Parts A and B: Number of Participants With Clinically Significant Physical Examination Abnormalities
Clinically significant physical examination abnormalities included weight decreased.
Time frame: Part A: Up to Day 57; Part B: Up to Day 169
Parts A and B: Number of Participants With Clinically Significant Neurological Examination Abnormalities
Clinically significant neurological examination abnormalities included hyporeflexia.
Time frame: Part A: Up to Day 57; Part B: Up to Day 169
Parts A and B: Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities
Time frame: Part A: Up to Day 57; Part B: Up to Day 169
Parts A and B: PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)
Time frame: Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85
Parts A and B: PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)
Time frame: Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85
Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h)
Time frame: Parts A and B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1
Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)
Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
Parts A and B: PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)
Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
Parts A and B: PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)
Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
Part C: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 28
The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 (no function) to 4 (full function), for a total possible score of 48. Scores decline with disease progression. ALSFRS-R scores calculated at diagnosis can be compared to scores throughout time to determine the speed of progression. Higher scores represent better function, negative change from baseline indicates disease progression.
Time frame: Baseline, Week 28 (Day 197)
Part B: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline
Total CSF SOD1 protein ratio to baseline was calculated.
Time frame: Day 85
Part C: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline
Total CSF SOD1 protein ratio to baseline was calculated and LS Geometric Mean ratio to baseline was reported.
Time frame: Week 28 (Day 197)
Part C: Neurofilament Light Chain (NfL) Plasma Concentration Ratio to Baseline
NfL is a biomarker whose concentration was assessed in plasma. Plasma NfL ratio to baseline was calculated.
Time frame: Baseline, Day 197 (Week 28)
Part C: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC) at Week 28
Vital capacity was measured by means of an SVC test, administered in the upright position.
Time frame: Baseline, Week 28 (Day 197)
Part C: Change From Baseline in Handheld Dynamometry (HHD) Megascore as Measured by the HHD Device at Week 28
Quantitative muscle strength was evaluated using HHD, which tests isometric strength of multiple muscles using standard participant positioning. Sixteen muscle groups were evaluated in both upper and lower extremities. The muscle strength values were normalized to Z scores as (post-baseline measurements - mean)/SD and averaged to provide HHD overall megascore. The overall megascore was created by averaging all eight bilateral measurement Z scores, if no more than 10 (≤ 10) measures are missing. A negative change from baseline indicated decreased muscle strength.
Time frame: Baseline, Week 28 (Day 197)
Part C: Time to Death or Permanent Ventilation
Time to Death or Permanent Ventilation is defined as the time to the earliest occurrence of one of the following events that were adjudicated by an independent committee: Death; Permanent ventilation (≥22 hours of mechanical ventilation \[invasive or noninvasive\] per day for ≥21 consecutive days).
Time frame: Baseline up to Week 28 (Day 197)
Part C: Time to Death
Time frame: Baseline up to Week 28 (Day 197)
Part C: Number of Participants Experiencing AEs and SAEs
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.
Time frame: First dose up to Day 236
Participants were enrolled at the investigative sites in the Belgium, Canada, Denmark, France, Germany, Italy, Japan, United Kingdom, and the United States from 20 January 2016 to 16 July 2021.
| Milestone | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 5 | 3 | 3 | 3 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 5 | 2 | 3 | 3 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Consent withdrawn | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 12 | 10 | 9 | 9 | 10 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 10 | 8 | 9 | 8 | 10 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Consent withdrawn | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36 | 72 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33 | 64 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 8 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Consent withdrawn | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.
| Participants | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| AEs | 2 | 2 | 3 | 3 | 6 | 12 | 10 | 9 | 9 | 10 |
| SAEs | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 0 |
Clinical laboratory assessments included hematology, chemistry, and urinalysis.
| Participants | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Pleocytosis | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 |
| Eosinophilia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Blood Phosphorus Decreased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| CSF Protein Increased | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 1 |
| CSF White Blood Cell Count Increased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| CSF White Blood Cell Count Positive | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Gamma-Glutamyltransferase Increased | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Urine Output Decreased | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
The criteria for clinically significant vital sign abnormalities include: Temperature: \>38 degree Celsius (°C) or an increase from baseline of ≥1°C; Pulse: \>120 beats per minute (bpm) or an increase from baseline of \>20 bpm, \<50 bpm or a decrease from baseline of \>20 bpm; Systolic blood pressure (BP): \>180 mmHg or an increase from baseline of \>40 mmHg, \<90 mmHg or a decrease from baseline of \>30 mmHg; Diastolic BP: \>105 mmHg or an increase from baseline of \>30 mmHg, \<50 mmHg or a decrease from baseline of \>20 mmHg.
| Participants | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Parts A and B: Number of Participants With Clinically Significant Vital Sign Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinically significant physical examination abnormalities included weight decreased.
| Participants | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Parts A and B: Number of Participants With Clinically Significant Physical Examination Abnormalities | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
Clinically significant neurological examination abnormalities included hyporeflexia.
| Participants | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Parts A and B: Number of Participants With Clinically Significant Neurological Examination Abnormalities | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Participants | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Increase From Baseline QTcF > 30 to 60 ms | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 2 | 3 |
| Maximum Post-baseline QTcF > 480 to 500 ms | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| ng/mL | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|
| Day 1 | 64.94 (38.8 to 159.0) | 75.06 (43.0 to 144.0) | 202.09 (174.0 to 236.0) | 529.63 (148.0 to 1450.0) | 80.75 (20.1 to 393.0) | 229.41 (26.3 to 948.0) | 437.28 (128.0 to 1930.0) | 1031.74 (285.0 to 3530.0) |
| Day 85 | — | — | — | — | 112.74 (29.7 to 203.0) | 199.69 (93.6 to 537.0) | 411.00 (74.1 to 1450.0) | 1181.83 (170.0 to 3990.0) |
| hours | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|
| Day 1 | 4.58 (4.0 to 6.0) | 4.16 (2.0 to 6.0) | 6.00 (6.0 to 6.0) | 2.70 (2.0 to 6.0) | 7.01 (2.0 to 24.0) | 3.68 (1.0 to 6.0) | 2.44 (1.0 to 6.0) | 3.67 (1.0 to 24.0) |
| Day 85 | — | — | — | — | 3.93 (2.0 to 6.0) | 3.97 (1.0 to 6.0) | 3.12 (1.0 to 6.0) | 3.82 (1.0 to 6.0) |
| hour*ng/mL | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|
| Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h) | 879.86 (550.8 to 1989.5) | 1027.18 (879.2 to 1263.2) | 2873.77 (2347.2 to 3543.4) | 5196.11 (2410.2 to 10977.3) | 1009.85 (372.8 to 2192.3) | 2875.13 (541.1 to 6984.8) | 4289.16 (1347.6 to 10637.1) | 11344.47 (4025.5 to 26143.0) |
| hour*ng/mL | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|
| Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| hour*ng/mL | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|
| Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| hours | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|
| Parts A and B: PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| hours | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|
| Parts A and B: PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 (no function) to 4 (full function), for a total possible score of 48. Scores decline with disease progression. ALSFRS-R scores calculated at diagnosis can be compared to scores throughout time to determine the speed of progression. Higher scores represent better function, negative change from baseline indicates disease progression.
| score on scale | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|
| Part C: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 28 | -8.1 ± 1.79 | -7.0 ± 1.42 |
Total CSF SOD1 protein ratio to baseline was calculated.
| ratio | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg |
|---|---|---|---|---|---|
| Part B: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline | 0.97 (0.83 to 1.13) | 0.99 (0.83 to 1.18) | 0.73 (0.61 to 0.87) | 0.79 (0.66 to 0.94) | 0.64 (0.55 to 0.76) |
Total CSF SOD1 protein ratio to baseline was calculated and LS Geometric Mean ratio to baseline was reported.
| ratio | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|
| Part C: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline | 1.16 (0.96 to 1.40) | 0.71 (0.62 to 0.83) |
NfL is a biomarker whose concentration was assessed in plasma. Plasma NfL ratio to baseline was calculated.
| ratio | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|
| Part C: Neurofilament Light Chain (NfL) Plasma Concentration Ratio to Baseline | 1.20 (0.94 to 1.52) | 0.40 (0.33 to 0.48) |
Vital capacity was measured by means of an SVC test, administered in the upright position.
| percent predicted | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|
| Part C: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC) at Week 28 | -22.20 ± 4.771 | -14.31 ± 3.557 |
Quantitative muscle strength was evaluated using HHD, which tests isometric strength of multiple muscles using standard participant positioning. Sixteen muscle groups were evaluated in both upper and lower extremities. The muscle strength values were normalized to Z scores as (post-baseline measurements - mean)/SD and averaged to provide HHD overall megascore. The overall megascore was created by averaging all eight bilateral measurement Z scores, if no more than 10 (≤ 10) measures are missing. A negative change from baseline indicated decreased muscle strength.
| score on a scale | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|
| Part C: Change From Baseline in Handheld Dynamometry (HHD) Megascore as Measured by the HHD Device at Week 28 | -0.37 ± 0.096 | -0.34 ± 0.073 |
Time to Death or Permanent Ventilation is defined as the time to the earliest occurrence of one of the following events that were adjudicated by an independent committee: Death; Permanent ventilation (≥22 hours of mechanical ventilation \[invasive or noninvasive\] per day for ≥21 consecutive days).
| days | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|
| Part C: Time to Death or Permanent Ventilation | NA (NA to NA) | NA (NA to NA) |
| days | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|
| Part C: Time to Death | NA (NA to NA) | NA (NA to NA) |
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.
| Participants | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|
| AEs | 34 | 69 |
| SAEs | 5 | 13 |
Collected over Part A: First dose up to Day 63; Part B: First dose up to Day 289; Part C: First dose up to Day 236. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A-SAD: Combined Placebo | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Part A-SAD: Cohort 1: BIIB067 10 mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part A-SAD: Cohort 2: BIIB067 20 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part A-SAD: Cohort 3: BIIB067 40 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part A-SAD: Cohort 4: BIIB067 60 mg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part B-MAD: Combined Placebo | 1/12 (8.3%) | 2/12 (16.7%) | 11/12 (91.7%) |
| Part B-MAD: Cohort 5: BIIB067 20 mg | 1/10 (10%) | 2/10 (20%) | 10/10 (100%) |
| Part B-MAD: Cohort 6: BIIB067 40 mg | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| Part B-MAD: Cohort 7: BIIB067 60 mg | 1/9 (11.1%) | 2/9 (22.2%) | 9/9 (100%) |
| Part B-MAD: Cohort 8: BIIB067 100 mg | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Part C-Pivotal: Placebo | 0/36 (0%) | 5/36 (13.9%) | 34/36 (94.4%) |
| Part C-Pivotal: BIIB067 100 mg | 1/72 (1.4%) | 13/72 (18.1%) | 68/72 (94.4%) |
| Event | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 1/12 | 0/10 | 1/9 | 1/9 | 0/10 | 0/36 | 1/72 |
| Csf protein increasedInvestigations | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 0/12 | 0/10 | 0/9 | 1/9 | 0/10 | 0/36 | 0/72 |
| Csf white blood cell count increasedInvestigations | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 0/12 | 0/10 | 0/9 | 1/9 | 0/10 | 0/36 | 0/72 |
| Cardiac failure congestiveCardiac disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 0/12 | 1/10 | 0/9 | 0/9 | 0/10 | 0/36 | 1/72 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 0/12 | 1/10 | 0/9 | 0/9 | 0/10 | 2/36 | 0/72 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 1/12 | 0/10 | 0/9 | 0/9 | 0/10 | 0/36 | 1/72 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 0/12 | 0/10 | 0/9 | 0/9 | 0/10 | 1/36 | 3/72 |
| DehydrationMetabolism and nutrition disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 0/12 | 0/10 | 0/9 | 0/9 | 0/10 | 1/36 | 0/72 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 0/12 | 0/10 | 0/9 | 0/9 | 0/10 | 1/36 | 0/72 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 0/12 | 0/10 | 0/9 | 0/9 | 0/10 | 0/36 | 2/72 |
| Event | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procedural painInjury, poisoning and procedural complications | 1/5 | 0/3 | 1/3 | 0/3 | 3/6 | 5/12 | 4/10 | 1/9 | 4/9 | 7/10 | 21/36 | 41/72 |
| HeadacheNervous system disorders | 0/5 | 0/3 | 2/3 | 1/3 | 1/6 | 7/12 | 4/10 | 2/9 | 4/9 | 6/10 | 16/36 | 33/72 |
| FallInjury, poisoning and procedural complications | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 3/12 | 3/10 | 3/9 | 2/9 | 5/10 | 15/36 | 17/72 |
| Back painMusculoskeletal and connective tissue disorders | 0/5 | 0/3 | 0/3 | 0/3 | 2/6 | 0/12 | 1/10 | 1/9 | 1/9 | 5/10 | 2/36 | 15/72 |
| Upper respiratory tract infectionInfections and infestations | 0/5 | 0/3 | 0/3 | 0/3 | 0/6 | 0/12 | 4/10 | 0/9 | 2/9 | 0/10 | 2/36 | 5/72 |
| Post lumbar puncture syndromeInjury, poisoning and procedural complications | 1/5 | 0/3 | 0/3 | 0/3 | 0/6 | 3/12 | 4/10 | 3/9 | 3/9 | 3/10 | 11/36 | 13/72 |
| Abdominal pain lowerGastrointestinal disorders | 0/5 | 0/3 | 0/3 | 1/3 | 0/6 | 0/12 | 0/10 | 0/9 | 0/9 | 0/10 | 0/36 | 0/72 |
| Faeces discolouredGastrointestinal disorders | 0/5 | 0/3 | 0/3 | 1/3 | 0/6 | 0/12 | 0/10 | 0/9 | 0/9 | 0/10 | 0/36 | 1/72 |
| Infusion site swellingGeneral disorders | 0/5 | 1/3 | 0/3 | 0/3 | 0/6 | 0/12 | 0/10 | 0/9 | 0/9 | 0/10 | 0/36 | 0/72 |
| PyrexiaGeneral disorders | 0/5 | 0/3 | 0/3 | 1/3 | 0/6 | 0/12 | 0/10 | 0/9 | 1/9 | 1/10 | 1/36 | 3/72 |
Intention-to-Treat (ITT) populations for parts A, B, and C included all randomized participants who received at least 1 dose or a part of 1 dose of study treatment (BIIB067 or placebo) in Parts A, B, and C respectively. The demographics data reported for Part B arm groups included only the unique participants who were enrolled directly into Part B of the study.
| Age, Continuous(years) | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 58.4 ± 9.29 | 50.3 ± 7.64 | 55.3 ± 17.62 | 49.0 ± 3.61 | 45.0 ± 12.82 | 49.2 ± 11.04 | 42.1 ± 11.19 | 57.5 ± 11.75 | 45.6 ± 10.71 | 48.9 ± 10.80 | 51.2 ± 11.57 | 48.1 ± 12.64 | 49.2 ± 12.02 |
| Sex: Female, Male(Participants) | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 0 | 1 | 4 | 5 | 3 | 5 | 3 | 6 | 17 | 29 | 78 |
| Male | 3 | 0 | 3 | 2 | 2 | 7 | 6 | 3 | 6 | 4 | 19 | 43 | 98 |
| Ethnicity (NIH/OMB)(Participants) | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 5 |
| Not Hispanic or Latino | 4 | 3 | 3 | 1 | 5 | 9 | 4 | 5 | 4 | 7 | 28 | 47 | 120 |
| Unknown or Not Reported | 1 | 0 | 0 | 2 | 1 | 3 | 5 | 3 | 5 | 3 | 7 | 21 | 51 |
| Race/Ethnicity, Customized(Participants) | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Race — Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 5 | 10 |
| Race — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race — White | 4 | 3 | 3 | 1 | 5 | 7 | 4 | 4 | 4 | 7 | 25 | 44 | 111 |
| Race — Not Reported | 1 | 0 | 0 | 2 | 1 | 3 | 5 | 3 | 5 | 3 | 7 | 21 | 51 |
| Race — Other | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)(score on a scale) | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | — | — | — | — | — | — | 35.4 ± 5.66 | 36.0 ± 6.40 | 35.78 ± 6.109 |
| Cerebrospinal Fluid (CSF) Levels of Total SOD1 Protein Concentration(nanograms per milliliter (ng/mL)) | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Geometric mean | — | — | — | — | — | 70.40 (57.2 to 87.9) | 102.00 (102.00 to 102.00) | 125.00 (125.00 to 125.00) | 82.80 (82.8 to 82.8) | 135.86 (92.5 to 199.0) | 107.07 (60.0 to 322.0) | 103.32 (38.8 to 282.0) | 104.64 (38.8 to 322.0) |
| Percentage Predicted Slow Vital Capacity (SVC)(percent predicted) | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | — | — | — | — | — | — | 83.7 ± 17.87 | 80.3 ± 14.22 | 81.50 ± 15.533 |
| Handheld Dynamometry (HHD) Megascore as Measured by the HHD Device(score on a scale) | Part A-SAD: Combined Placebo | Part A-SAD: Cohort 1: BIIB067 10 mg | Part A-SAD: Cohort 2: BIIB067 20 mg | Part A-SAD: Cohort 3: BIIB067 40 mg | Part A-SAD: Cohort 4: BIIB067 60 mg | Part B-MAD: Combined Placebo | Part B-MAD: Cohort 5: BIIB067 20 mg | Part B-MAD: Cohort 6: BIIB067 40 mg | Part B-MAD: Cohort 7: BIIB067 60 mg | Part B-MAD: Cohort 8: BIIB067 100 mg | Part C-Pivotal: Placebo | Part C-Pivotal: BIIB067 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | — | — | — | — | — | — | 0.0 ± 0.60 | 0.0 ± 0.67 | -0.007 ± 0.6396 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/
Data sharing details ↗ · vivli.org
Ran from Jan 2016 to primary completion in Jul 2021, 65 months.
Results were first posted in Jul 2023, 2 years after primary completion. A results delay was requested in Jul 2022.
Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 65 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofersen
Amyotrophic Lateral Sclerosis →